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OBJECTIVE: There is ongoing discussion in the Nether-
lands about the introduction of hepatitis B (HepB) vacci-
nation into the national immunisation program. The pur-
pose of this study was to analyze the cost-effectiveness of
general vaccination of newborns in addition to the current
policy, screening of pregnant women and subsequent im-
munisation of newborns from HBsAg- mothers (“screen 
vaccinate”) in comparison with the current strategy of
screening only (“screening only”), from a health care
payer perspective. METHODS: The incidence of HepB
infection over the next 50 years was simulated with a dy-
namic model, describing a population of age 0–60 years,
with 6 sexual activity classes (both for hetero- and homo-
sexual groups). Immigration from more endemic countries
was modelled as yearly additional incidence of carriers in
the population. Progress of disease after infection was
computed with a Markov-chain model, that predicted fu-
ture patient numbers, life-time costs of infection, and life-
years lost after infection. The main outcome parameter
was cost per life-years gained. Costs (in 1999 EUR) and
effects were discounted at 4%. RESULTS: Cost per life
year gained appeared to be highly sensitive to the as-
sumed percentage of carriers among immigrants, vaccina-
tion costs and to discounting of effects. Cost per life year
gained in the screen  vaccinate scenario ranged from
approximately EUR 25,000 (6% carriers among immi-
grants) to EUR 75,000 (1% carriers among immigrants).
If effects were not discounted, cost per life year gained
were below EUR 9,000 in all models explored.
CONCLUSIONS: Compared to other interventions, hep-
atitis B vaccination is not cost-effective in low endemic
countries such as the Netherlands. However, this conclu-
sion depends heavily on the convention to discount ef-
fects at a similar rate as costs. The application of stan-
dard methodology is unfavourable for programs that
prevent negative health outcomes in the mid- to long-
term.
PID4
HOSPITAL ANTIBIOTICS
UTILIZATION EVALUATION
Caicoya M, Natal C
Clinical Epidemiology and Preventive Medicine Service, 
Hospital Monte Naranco, Oviedo, Spain
OBJECTIVE: 1) To describe the frequency and distribu-
tion of hospital antibiotics use. 2) To evaluate the appro-
priateness of the prescription to diagnostic and therapeu-
tic criteria. METHODS: It is an observational cross-
sectional study of 411 clinical records obtained by ran-
dom sampling over all hospital discharges between 01/
01/99 al 31/09/99. Information was sought on the fol-
lowing variables: identification, diagnosis, process indi-
cators, treatment changes and causes, indicators of clini-
cal evolution, and diagnostic and prescription criteria.
The information was collected and reviewed by the au-
thors. Criteria of infection and those of appropriateness
of prescription were obtained from the Centres for Dis-
ease Control and others scientific societies. RESULTS:
Antibiotics prescription was registered on the clinical
record in 25% of cases; 49% of antibiotic treatments
were prescribed in the hospital, 30% of them were treat-
ment changes, while 51% of antibiotic treatments were
prescribed in the reference hospital. Amoxicillin-Clavu-
lanate combination and ofloxacin account for 88% of
the prescriptions in the HMN and 76% of the total anti-
biotic treatments. Between 44% and 61% of the diagno-
sis were adequate to the criteria, with a mean of 54%,
and between 91% and 100% were appropriate prescrip-
tions. Mean treatment length was 9.6 days, and only
14% of the urinary tract infection treatment length was
correct; an intravenous catheter was kept 80% of the
treatment. DISCUSSION: While most of the antibiotic
prescription in this study were appropriate to the clinical
diagnosis, only half of the diagnosis were in keep with
the diagnostic criteria used in this study and the urinary
tract infection as well as the intravenous duration treat-
ment appear to be long. The consequences of these find-
ings are increased cost and iatrogenia. The adequacy of
diagnosis to objective criteria and the duration on treat-
ment, especially intravenous treatment, are the main ar-
eas for improving. The recommended strategies are: 1)
utilization consensus 2) training programs 3) medical au-
dits 4) development of diagnostic and therapeutic criteria
adapted to the hospital.
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OBJECTIVES: Influenza is a highly contagious disease
that remains a major cause of morbidity and mortality in
Europe. The socio-economic impact of the disease is un-
derestimated. The study aimed to model options for in-
fluenza management in three European countries (France,
Germany, United Kingdom). METHODS: Cost-of-illness
(COI) and cost-effectiveness (CE) models were developed
to assess the economics of influenza prevention for de-
fined adult groups (employed people, elderly, high-risk
patients). The initial models were developed based on in-
ternational and UK published data. Treatment efficacy
and the general epidemiology of influenza were assumed
to be similar for the three countries. The adaptation of
the general models was based on: 1) a country specific lit-
erature review was performed to collect baseline models
parameters: patient demographics, epidemiology, attack
rate, occurrence probabilities, complications and death,
current treatment patterns, general and specific clinical
practice guidelines, clinical effectiveness of current thera-
pies, medical resource utilization and productivity loss;
